2022 ESG Performance Highlights

2022 ESG performance highlights Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. With commercial representation in more than 130 countries and 45,000 employees around the world, we understand that our impact as a health care company extends to how we operate our business and care for the world around us. Our ESG performance in 2022 Environment 20% decrease in global 71% of all Boston Scientific real estate (including commercial, leased energy intensity since 2017 and owned) is independently certified for energy efficiency by industry-leading bodies such as LEED for design and ISO 50001:2018 for building operations, representing 6+ million square feet 76% renewable electricity, 40% of energy from Remained on track for on track for our goal of renewable sources, on track carbon neutrality (scope 1 and 2) in all our 1,2 1 100% by 2024 for our goal of 90% by 2027 manufacturing and key distribution sites by 2030 SBTi approval Net-zero and greenhouse gas emission reduction targets approved by the Science Based Targets initiative (SBTi) Note: All data as of December 31, 2022 unless otherwise specified. 1 Inclusive of all manufacturing and key distribution sites only. 2 Purchased electricity matched with electricity from renewable sources.

Social 33+ million patients served $67 million donated to fund 121,000+ women and medical research, fellowships, people of color identified education and charitable in action plans to advance $1.3+ billioninvested in organizations globally equitable care through our R&D for products to advance Close the Gap initiative 3 patient care Scored 80% or higher As a result of our 3Up by 2023 efforts, we achieved: in employee engagement • 42.6% supervisor and manager roles held by women (global) survey indices for engagement, satisfaction and pride in • 22.6% supervisor and manager roles held by multicultural working for Boston Scientific employees (U.S./Puerto Rico) 4 75% of director level and 99%+pay equity 12.3% employee voluntary above open positions hired turnover rate from within Governance ~37 million 97% effectiveness in 0 findings resulting in products delivered corrective and preventive action following more than action (CAPA) metrics and 325 external audit days 99% on-time approvals 35% increased investment ESG scorecard part of our annual employee bonus program in cybersecurity Implemented zero-trust Board experience cybersecurity model Board of director member experience includes medical device, focused on user, assets and risk management, technology, quality and financial literacy resources to strengthen our resilience against cyber threats Board independence 30% of board of director A significant majority of our Board of Directors qualify as independent under the New York Stock Exchange’s Corporate members self-identify as Governance Standards, including a lead independent director women, 30% self-identify as ethnically diverse5 Note: All data as of December 31, 2022 unless otherwise specified. 3 Represents GAAP R&D expense per 2022 Annual Report on Form 10-K. 4 Figure from 2021 results. Analysis is completed every other year. 5 Donna James will remain in her role as a director of the Company until her resignation becomes effective on the day of the 2023 Annual Meeting of Stockholders, which is scheduled to occur on May 4, 2023.